Diabetes, Metabolic Syndrome and Obesity (Oct 2020)
The Association Between Femoral Artery Intima-Media Thickness and Serum Glucagon-Like Peptide-1 Levels Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus
Abstract
Tuan Dinh Le, 1,* Nga Phi Thi Nguyen, 2, 3,* Son Tien Nguyen, 2, 3 Hien Thi Nguyen, 4 Hoa Thanh Thi Tran, 5 Thi Ho Lan Nguyen, 6 Cuong Duy Nguyen, 7 Giang Thi Nguyen, 6 Xuan Thanh Nguyen, 8 Bac Duy Nguyen, 9 Son The Trinh, 10 Tuan Anh Ngo, 11 Binh Nhu Do, 12, 13 Thuc Cong Luong 8, 14 1Department of Internal Medicine, Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam; 2Department of Endocrinology, Military Hospital 103, Ha Noi, Vietnam; 3Department of Rheumatology and Endocrinology, Vietnam Military Medical University, Ha Noi, Vietnam; 4Department of Physiology, Thai Binh university of Medicine and Pharmacy, Thai Binh, Vietnam; 5Department of Intensive Care Unit, National Hospital of Endocrinology, Ha Noi, Vietnam; 6Department of Internal Medicine, National Hospital of Endocrinology, Ha Noi, Vietnam; 7Department of Intensive Care Unit, Thai Binh university of Medicine and Pharmacy, Thai Binh, Vietnam; 8Department of Vascular Cardiology, Military Hospital 103, Ha Noi, Vietnam; 9Department of Anatomy, Vietnam Military Medical University, Ha Noi, Vietnam; 10Military Institute of ClinicalEmbryology and Histology, Vietnam Military Medical University, Ha Noi, Vietnam; 11Department of Health Economic, Vietnam Military Medical University, Ha Noi, Vietnam; 12Department of Infectious Disease, Vietnam Military Medical University, Ha Noi, Vietnam; 13Division of Military Science, Military Hospital 103, Ha Noi, Vietnam; 14Director Office, Military Hospital 103, Ha Noi, Vietnam*These authors contributed equally to this workCorrespondence: Thuc Cong Luong; Son The Trinh Email [email protected]; [email protected]: Endothelium dysfunction and decrease of incretin effects occur early in type 2 diabetes mellitus and these changes contribute to diabetic cardiovascular complications such as atherosclerosis, thick intima-media, coronary, and peripheral arterial diseases. In patients with diabetes, the femoral artery is a site of a high incidence of injury in peripheral vascular diseases, and atherosclerotic changes may appear earlier in the femoral artery compared to the carotid artery. This study was conducted to determine the prevalence of increased femoral artery intima-media thickness (IMT) and atherosclerotic plaque and their correlation with serum glucagon-like peptide-1 (GLP-1) levels in newly-diagnosed patients with type 2 diabetes mellitus.Materials and Methods: A cross-sectional study was conducted on 332 patients with nT2D in the National Endocrinology Hospital, Vietnam from January 2015 to May 2018. IMT was measured by Doppler ultrasound and GLP-1 by enzyme-linked immunosorbent assay (ELISA). All data were analyzed with SPSS version 26 for Windows (SPSS Inc, Chicago, IL).Results: Prevalence of thick femoral artery IMT and atherosclerotic plaque was 38.2 and 22.3%, respectively. There was a relationship between IMT and age, waist to hip ratio (WHR), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting GLP-1, high sensitive CRP (hsCRP) and 24-hour microalbuminuria secretion (24-h MAUS). The fasting serum GLP-1 (fGLP-1) levels were reduced significantly in patients with thickness and atherosclerosis femoral artery (p = 0.001). After adjusting with other related factors, namely, DBP and estimated glomerular filtration rate (eGFR), whilst hsCRP and 24-h MAUS showed a significantly positive correlation to IMT (Standardized B and p of 0.242, 0.004 and 0.178, 0.043, respectively), fGLP-1 showed a significantly negative correlation to IMT (Standardized B = − 0.288, p = 0.001).Conclusion: Among n2TD, the percentage for femoral artery thick IMT and atherosclerosis was 38.2% and 22.3% respectively, and serum GLP-1 was negatively correlated with thick IMT and atherosclerosis.Keywords: newly diagnosed type 2 diabetes mellitus, intima-media thickness and atherosclerotic plaque, femoral artery, serum glucagon-like peptide-1 levels
